The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Podcasts|July 30, 2021
Core2Write – Eliminate Particulates & Fibers in the Core
Author(s)Veltek Associates, Inc.
GMP firms have a constant struggle with the task of reducing fibers, particulates, and microorganisms within classified areas. A main source of this problem is paper products used to document operations. Veltek Associates, Inc. has developed an innovative way to address and solve problems surrounding particulate and fiber shedding from cleanroom documentation with our CleanPrint 10® synthetic writing substrate, Core2Write® customized documentation, and Core2Print® HEPA filtered cleanroom printing system.
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
3
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5